Summit Creek Advisors LLC Sells 15,817 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Summit Creek Advisors LLC reduced its stake in shares of Omnicell, Inc. (NASDAQ:OMCLFree Report) by 7.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 190,048 shares of the company’s stock after selling 15,817 shares during the period. Summit Creek Advisors LLC owned 0.42% of Omnicell worth $7,152,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Covestor Ltd lifted its stake in shares of Omnicell by 65.6% in the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock worth $61,000 after acquiring an additional 537 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Omnicell during the third quarter worth $62,000. Neo Ivy Capital Management acquired a new position in Omnicell in the third quarter valued at $78,000. Fifth Third Bancorp boosted its position in Omnicell by 143.2% during the third quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock valued at $100,000 after acquiring an additional 1,313 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Omnicell by 110.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,392 shares of the company’s stock worth $153,000 after acquiring an additional 1,777 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Stock Up 2.2 %

OMCL traded up $0.66 during mid-day trading on Monday, reaching $30.78. 302,850 shares of the stock were exchanged, compared to its average volume of 536,008. Omnicell, Inc. has a 1 year low of $25.69 and a 1 year high of $77.14. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38. The stock has a market capitalization of $1.41 billion, a PE ratio of -67.96, a price-to-earnings-growth ratio of 136.35 and a beta of 0.77. The company has a 50 day moving average price of $28.06 and a two-hundred day moving average price of $31.37.

Omnicell (NASDAQ:OMCLGet Free Report) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The business had revenue of $258.85 million during the quarter, compared to the consensus estimate of $256.00 million. As a group, research analysts anticipate that Omnicell, Inc. will post 0.16 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Benchmark reaffirmed a “buy” rating and set a $38.00 target price on shares of Omnicell in a research note on Tuesday, April 30th. Wells Fargo & Company decreased their price target on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. Based on data from, the stock currently has a consensus rating of “Hold” and an average price target of $42.20.

Check Out Our Latest Stock Analysis on Omnicell

About Omnicell

(Free Report)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Featured Stories

Want to see what other hedge funds are holding OMCL? Visit to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCLFree Report).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with's FREE daily email newsletter.